Halozyme is a biopharmaceutical company dedicated to the development and commercialization of products targeting the area outside the cell known as the extracellular matrix, or Matrix. The Matrix provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. We have developed unique scientific expertise in the Matrix that allows us to pursue this target rich environment for generating product candidate leads.
The company's portfolio of products is primarily based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that alter the Matrix. Our lead enzyme, rHuPH20, or hyaluronidase, is an example of a Matrix modifying enzyme. By temporarily degrading hyaluronan (HA), a key component in the skin, rHuPH20 facilitates the delivery of drugs and fluids through the Matrix and into circulation. Halozyme’s rHuPH20 is the underlying drug delivery technology of both HYLENEX® for generic small molecules and fluids, and Enhanze technology for proprietary small and large molecules. We are also seeking ways to combine or formulate rHuPH20 with previously approved small molecule drugs to develop new proprietary products.
